Chardan Capital Markets initiated coverage on Xilio Therapeutics with a new price target

12/21/22 7:57:28 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Chardan Capital Markets initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $7.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$XLO

Date	Price Target	Rating	Analyst
12/21/2022	$7.00	Buy	Chardan Capital Markets
1/10/2022	$36.00	Buy	HC Wainwright & Co.
11/16/2021	$40.00	Buy	Guggenheim
11/16/2021	$31.00	Outperform	Raymond James
11/16/2021		Outperform	Cowen & Co.
11/16/2021	$32.00	Overweight	Morgan Stanley